BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure

Heart Failure Reviews

Volumn 19, Issue 4, 2014, Pages 471-505

  Oremus, Mark ^a   Don Wauchope, Andrew ^a   McKelvie, Robert ^a   Santaguida, Pasqualina L ^a   Hill, Stephen ^a   Balion, Cynthia ^a   Booth, Ronald ^b   Brown, Judy A ^a   Ali, Usman ^a   Bustamam, Amy ^a   Sohel, Nazmul ^a   Raina, Parminder ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

BNP; Chronic; Heart failure; NT proBNP; Prognosis; Stable; Systematic review

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; HEART FAILURE; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN DETERMINATION; RISK ASSESSMENT; SYSTEMATIC REVIEW; BLOOD; CAUSE OF DEATH; HEALTH;

CAUSE OF DEATH; GLOBAL HEALTH; HEART FAILURE; HUMANS; MORBIDITY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 84906349912     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-014-9439-6     Document Type: Article

References (113)

1. National Clinical Guideline Centre (2010) Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. NICE clinical guideline 108. National Institute for Health and Clinical Excellence, Manchester. http://www.nice.org.uk/nicemedia/live/13099/50517/50517. pdf
2. McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A et al (2013) The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol 29:168-181. doi:10.1016/j.cjca.2012.10.007
3. McMurray JJV, Adamopoulos C, Anker S, Auricchio A (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 33:1787-1847
4. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D et al (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circ Cardiovasc Qual Outcomes 120:2177-2187. doi:10.1161/CIRCULATIONAHA.109.884866
5. Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330:625. doi:10.1136/bmj.330.7492.62
6. Vesbianu D, Vesbianu C, Bernstein P, Kouides R (2008) Plasma brain natriuretic peptide - an independent predictor of mortality and rehospitalization in congestive heart failure - a meta-analysis. World Heart J 1:349-354
7. Oremus M, Raina PS, Santaguida P, Balion CM, McQueen MJ, McKelvie R et al (2008) A systematic review of BNP as a predictor of prognosis in persons with coronary artery disease. Clin Biochem 41:260-265. doi:10.1016/j.clinbiochem. 2007.09.011 (Pubitemid 351240898)
8. Balion C, Santaguida PL, Hill S, Worster A, McQueen M, Oremus M, McKelvie R, Booker L, Fagbemi J, Reichert S, Raina P (2006) Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. AHRQ publication no. 06-E014. AHRQ, Rockville
9. Hayden JA, Côté P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144:427-437. doi:10.7326/0003-4819-144-6-200603210-00010
10. Vrtovec B, Delgado R, Zewail A, Thomas CD, Richartz BM, Radovancevic B (2003) Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circ Cardiovasc Qual Outcomes 107:1764-1769. doi:10.1161/01.cir.0000057980.84624.95 (Pubitemid 36418357)
11. Horwich TB, Hamilton MA, Fonarow GC (2006) B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 47:85-90. doi:10.1016/j.jacc.2005.08.050 (Pubitemid 43005169)
12. Ralli S, Horwich TB, Fonarow GC (2005) Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 150:1220-1227. doi:10.1016/j.ahj.2005.01.049 (Pubitemid 41773526)
13. Meyer B, Mörtl D, Strecker K, Hülsmann M, Kulemann V, Neunteufl T et al (2005) Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol 46:1011-1018. doi:10.1016/j.jacc.2005.04.060
14. Krüger S, Graf J, Merx MW, Stickel T, Kunz D, Koch KC et al (2006) The value of cardiopulmonary exercise testing and brain natriuretic peptide plasma levels in predicting the prognosis of patients with chronic heart failure. Eur J Intern Med 17:96-101. doi:10.1016/j.ejim.2005.11.001
15. Kozdag G, Ertas G, Kilic T, Acar E, Sahin T, Ural D (2010) Triiodothyronine and brain natriuretic peptide: similar long-term prognostic values for chronic heart failure. Tex Heart Inst J 37:538-546
16. Dries DL, Ky B, Wu AH, Rame JE, Putt ME, Cappola TP (2010) Simultaneous assessment of unprocessed ProBNP1-108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure. Circ Heart Fail 3:220-227. doi:10.1161/CIRCHEARTFAILURE.109.903153
17. Boffa GM, Zaninotto M, Sartor R, Mion M, Berton A, Pasqualetto C et al (2009) Interleukin-6 and tumor necrosis factor-alpha as biochemical markers of heart failure: a head-to-head clinical comparison with B-type natriuretic peptide. J Cardiovasc Med (Hagerstown) 10:758-764. doi:10.2459/JCM. 0b013e32832ce8e2
18. Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG et al (2009) Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 53:1783-1790. doi:10.1016/j.jacc.2009.01.057
19. Adlbrecht C, Hulsmann M, Strunk G, Berger R, Mortl D, Struck J et al (2009) Prognostic value of plasma midregional proadrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 11:361-366. doi:10.1093/eurjhf/hfp004
20. Scardovi AB, De Maria R, Celestini A, Coletta C, Aspromonte N, Perna S et al (2008) Prognostic value of brain natriuretic peptide and enhanced ventilatory response to exercise in patients with chronic heart failure. Intern Emerg Med 3:331-337. doi:10.1007/s11739-008-0163-x
21. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG et al (2008) Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 52:266-272. doi:10.1016/j.jacc.2008.03.050 (Pubitemid 351957847)
22. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel TT et al (2008) Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 14:140-144. doi:10.1016/j.cardfail.2007.10.013
23. Popescu BA, Popescu AC, Antonini-Canterin F, Rubin D, Cappelletti P, Piazza R et al (2007) Prognostic role of left atrial volume in elderly patients with symptomatic stable chronic heart failure: comparison with left ventricular diastolic dysfunction and B-type natriuretic peptide. Echocardiography 24:1035-1043. doi:10.1111/j.1540-8175.2007.00540.x (Pubitemid 350125447)
24. Scardovi AB, De Maria R, Coletta C, Aspromonte N, Perna S, Cacciatore G et al (2007) Multiparametric risk stratification in patients with mild to moderate chronic heart failure. J Card Fail 13:445-451. doi:10.1016/j.cardfail. 2007.03.003 (Pubitemid 47179909)
25. Bermingham M, O'Callaghan E, Dawkins I, Miwa S, Samsudin S, McDonald K et al (2011) Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail 13:885-891. doi:10.1093/eurjhf/hfr063
26. Rothenburger M, Wichter T, Schmid C, Stypmann J, Tjan TD, Berendes E et al (2004) Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. J Heart Lung Transplant 23:1189-1197. doi:10.1016/j.healun.2004.07.006 (Pubitemid 39346236)
27. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA (2003) N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24:1735-1743. doi:10.1016/j.ehj.2003.07.005 (Pubitemid 37236862)
28. Gardner RS, Chong V, Morton I, McDonagh TA (2005) N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation. Eur J Heart Fail 7:253-260. doi:10.1016/j.ejheart.2004.06.002 (Pubitemid 40215621)
29. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P et al (2004) Prognostic impact of plasma N-terminal probrain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circ Cardiovasc Qual Outcomes 110:1780-1786. doi:10.1161/01.CIR.0000143059.68996.A7 (Pubitemid 39302655)
30. Corell P, Gustafsson F, Kistorp C, Madsen LH, Schou M, Hildebrandt P (2007) Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. Int J Cardiol 117:395-402. doi:10.1016/j.ijcard.2006.03.084 (Pubitemid 46507632)
31. Schou M, Gustafsson F, Corell P, Kistorp CN, Kjaer A, Hildebrandt PR (2007) The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure. Am Heart J 154:123-129. doi:10.1016/j.ahj.2007.04.002 (Pubitemid 46920487)
32. Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G et al (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circ Heart Fail 115:1754-1761. doi:10.1161/CIRCULATIONAHA.106.653964
33. Mikkelsen KV, Møller JE, Bie P, Ryde H, Videbaek L, Haghfelt T (2006) Tei index and neurohormonal activation in patients with incident heart failure: serial changes and prognostic value. Eur J Heart Fail 8:599-608. doi:10.1016/j.ejheart.2005.11.015
34. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M et al (2006) Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circ Cardiovasc Qual Outcomes 114:1829-1837. doi:10.1161/CIRCULATIONAHA.106.649426 (Pubitemid 44673358)
35. Bruch C, Reinecke H, Stypmann J, Rothenburger M, Schmid C, Breithardt G et al (2006) N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure. J Heart Lung Transplant 25:1135-1141. doi:10.1016/j.healun.2006.05.006 (Pubitemid 44311523)
36. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S et al (2006) Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 52:1528-1538. doi:10.1373/clinchem.2006.069575 (Pubitemid 44148316)
37. Bruch C, Rothenburger M, Gotzmann M, Sindermann J, Scheld HH, Breithardt G et al (2006) Risk stratification in chronic heart failure: independent and incremental prognostic value of echocardiography and brain natriuretic peptide and its N-terminal fragment. J Am Soc Echocardiogr 19:522-528. doi:10.1016/j.echo.2005.12.027
38. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A et al (2005) Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circ Cardiovasc Qual Outcomes 112:1756-1762. doi:10.1161/CIRCULATIONAHA.104.530972 (Pubitemid 41372115)
39. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G (2005) Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150:484-487. doi:10.1016/j.ahj.2004.11.016 (Pubitemid 41317618)
40. George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T et al (2005) Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 165:1304-1309. doi:10.1001/archinte.165.11.1304 (Pubitemid 40989597)
41. Gardner RS, Chong KS, Morton JJ, McDonagh TA (2005) N-terminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure. J Card Fail 11:S47-S53. doi:10.1016/j.cardfail.2005.04. 008
42. Gardner RS, Henderson G, McDonagh TA (2005) The prognostic use of right heart catheterization data in patients with advanced heart failure: how relevant are invasive procedures in the risk stratification of advanced heart failure in the era of neurohormones? J Heart Lung Transplant 24:303-309. doi:10.1016/j.healun.2004.01.010 (Pubitemid 40312055)
43. Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, O'Connor CM, Adams KF Jr et al (2007) Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 167:367-373. doi:10.1001/archinte. 167.4.367 (Pubitemid 46333937)
44. Jankowska EA, Drohomirecka A, Ponikowska B, Witkowska A, Lopuszanska M, Szklarska A et al (2010) Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. Eur J Heart Fail 12:966-973. doi:10.1093/eurjhf/hfq108
45. Codognotto M, Piccoli A, Zaninotto M, Mion MM, Ruzza L, Barchita A et al (2010) Effect of a dialysis session on the prognostic values of NT-proBNP, troponins, endothelial damage and inflammation biomarkers. J Nephrol 23:465-471
46. Dini FL, Gabutti A, Passino C, Fontanive P, Emdin M, De Tommasi SM (2010) Atrial fibrillation and amino-terminal probrain natriuretic peptide as independent predictors of prognosis in systolic heart failure. Int J Cardiol 140:344-350. doi:10.1016/j.ijcard.2008.11.108
47. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S et al (2010) N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 55:645-653. doi:10.1016/j.jacc.2009.08.078
48. Tsutamoto T, Kawahara C, Nishiyama K, Yamaji M, Fujii M, Yamamoto T et al (2010) Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure. Am Heart J 159:63-67. doi:10.1016/j.ahj.2009.10.022
49. Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Yamamoto T, Fujii M et al (2009) Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure - special reference to transcardiac gradient of norepinephrine. Circ J 73:2270-2275. doi:10.1253/circj.CJ-09-0456
50. Al-Najjar Y, Goode KM, Zhang J, Cleland JG, Clark AL (2009) Red cell distribution width: an inexpensive and powerful prognostic marker in heart failure. Eur J Heart Fail 11:1155-1162. doi:10.1093/eurjhf/hfp147
51. Frankenstein L, Zugck C, Nelles M, Schellberg D, Katus HA, Remppis BA (2009) The obesity paradox in stable chronic heart failure does not persist after matching for indicators of disease severity and confounders. Eur J Heart Fail 11:1189-1194. doi:10.1093/eurjhf/hfp150
52. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C et al (2009) Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 54:1850-1859. doi:10.1016/j.jacc.2009.06.041
53. Charach G, George J, Afek A, Wexler D, Sheps D, Keren G et al (2009) Antibodies to oxidized LDL as predictors of morbidity and mortality in patients with chronic heart failure. J Card Fail 15:770-774. doi:10.1016/j.cardfail.2009. 05.009
54. Zielinski T, Browarek A, Zembala M, Sadowski J, Zakliczynski M, Przybylowski P et al (2009) Risk stratification of patients with severe heart failure awaiting heart transplantation - Prospective National Registry POLKARD HF. Transplant Proc 41:3161-3165. doi:10.1016/j.transproceed.2009.09.049
55. Poletti R, Passino C, Giannoni A, Zyw L, Prontera C, Bramanti F et al (2009) Risk factors and prognostic value of daytime Cheyne-Stokes respiration in chronic heart failure patients. Int J Cardiol 137:47-53. doi:10.1016/j.ijcard. 2008.06.028
56. Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL et al (2009) Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 15:565-571. doi:10.1016/j.cardfail.2009.01.014
57. Dini FL, Fontanive P, Buralli S, Panicucci E, Andreini D, Conti U et al (2009) N-terminal protype-B natriuretic peptide and Doppler diastolic variables are incremental for risk stratification of patients with NYHA class I-II systolic heart failure. Int J Cardiol 136:144-150. doi:10.1016/j.ijcard.2008.04. 032
58. Vazquez R, Bayes-Genis A, Cygankiewicz I, Pascual-Figal D, Grigorian-Shamagian L, Pavon R et al (2009) The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 30:1088-1096. doi:10.1093/eurheartj/ehp032
59. Frankenstein L, Clark AL, Goode K, Ingle L, Remppis A, Schellberg D et al (2009) The prognostic value of individual NT-proBNP values in chronic heart failure does not change with advancing age. Heart 95:825-829. doi:10.1136/hrt.2008.158626
60. Kubánek M, Goode KM, Lánská V, Clark AL, Cleland JG (2009) The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 11:367-377. doi:10.1093/eurjhf/hfp003
61. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH et al (2009) Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 11:281-291. doi:10.1093/eurjhf/ hfn046
62. Koç M, Bozkurt A, Yildiray-Sahin D, Unal I, Acartürk E (2009) Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure. Cardiol J 16:43-49
63. Michowitz Y, Kisil S, Guzner-Gur H, Rubinstein A, Wexler D, Sheps D et al (2008) Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure. Isr Med Assoc J 10:884-888
64. Honold J, Geiger L, Assmus B, Fischer-Rasokat U, Schaechinger V, Zeiher AM et al (2008) The initial slope of the VCO2/VO2-curve (s1) in cardiopulmonary exercise testing is a strong and independent predictor of outcome in patients with previous myocardial infarction. Clin Res Cardiol 97:882-890. doi:10.1007/s00392-008-701-6
65. Tsutamoto T, Nishiyama K, Sakai H, Tanaka T, Fujii M, Yamamoto T et al (2008) Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure. Eur J Heart Fail 10:1208-1214. doi:10.1016/j.ejheart. 2008.09.011
66. Hinderliter AL, Blumenthal JA, O'Conner C, Adams KF, Dupree CS, Waugh RA et al (2008) Independent prognostic value of echocardiography and N-terminal pro-B-type natriuretic peptide in patients with heart failure. Am Heart J 156:1191-1195. doi:10.1016/j.ahj.2008.07.022
67. Frankenstein L, Remppis A, Nelles M, Schaelling B, Schellberg D, Katus H et al (2008) Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. Eur Heart J 29:2634-2640. doi:10.1093/eurheartj/ehn388
68. Kallistratos MS, Dritsas A, Laoutaris ID, Cokkinos DV (2008) Incremental value of N-terminal pro-brain natriuretic peptide over left ventricle ejection fraction and aerobic capacity for estimating prognosis in heart failure patients. J Heart Lung Transplant 27:1251-1256. doi:10.1016/j.healun.2008.07.030
69. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T et al (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997-1003. doi:10.1016/j.jacc.2008.04.069
70. Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K et al (2008) Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 102:733-737. doi:10.1016/j.amjcard.2008.04.048
71. Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R (2008) Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic peptide in patients with heart failure with versus without chronic kidney disease. Am J Cardiol 102:469-474. doi:10.1016/j.amjcard.2008.03.082
72. Dini FL, Fontanive P, Panicucci E, Andreini D, Chella P, De Tommasi SM (2008) Prognostic significance of tricuspid annular motion and plasma NT-proBNP in patients with heart failure and moderate-to-severe functional mitral regurgitation. Eur J Heart Fail 10:573-580. doi:10.1016/j.ejheart.2008.04.003
73. Amir O, Paz H, Ammar R, Yaniv N, Schliamser JE, and Lewis BS (2008) Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center. Isr Med Assoc J 10:109-12. http://www.ima.org.il/IMAJ/ ViewArticle.aspx?year=2008&month=02&page=109 (Pubitemid 351649633)
74. Pascual-Figal DA, Domingo M, Casas T, Gich I, Ordóñnez- Llanos J, Martinez P et al (2008) Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 29:1011-1018. doi:10.1093/eurheartj/ehn023 (Pubitemid 351844674)
75. Moertl D, Hammer A, Huelsmann M, Pacher R, Berger R (2008) Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients. Eur J Heart Fail 10:404-411. doi:10.1016/j.ejheart.2008.02.018
76. Koç M, Bozkurt A, Acarturk E, Sahin DY, Unal I (2008) Usefulness of N-terminal pro-B-type natriuretic peptide increase with exercise for predicting cardiovascular mortality in patients with heart failure. Am J Cardiol 101:1157-1162. doi:10.1016/j.amjcard.2007.11.070
77. Pfister R, Diedrichs H, Schiedermair A, Rosenkranz S, Hellmich M, Erdmann E et al (2008) Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail 10:315-320. doi:10.1016/j.ejheart.2008.01.009
78. Gardner RS, Chong KS, O'Meara E, Jardine A, Ford I, McDonagh TA (2007) Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. Eur Heart J 28:3027-3033. doi:10.1093/eurheartj/ehm480 (Pubitemid 350262260)
79. Tsutamoto T, Sakai H, Nishiyama K, Tanaka T, Fujii M, Yamamoto T et al (2007) Direct comparison of transcardiac increase in brain natriuretic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure. Circ J 71:1873-1878. doi:10.1253/circj.71.1873 (Pubitemid 350261409)
80. von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P et al (2007) Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 50:1973-1980. doi:10.1016/j.jacc.2007.08.012 (Pubitemid 350046336)
81. Schou M, Gustafsson F, Kistorp CN, Corell P, Kjaer A, Hildebrandt PR (2007) Prognostic usefulness of anemia and N-terminal pro-brain natriuretic peptide in outpatients with systolic heart failure. Am J Cardiol 100:1571-1576. doi:10.1016/j.amjcard.2007.06.064 (Pubitemid 350050866)
82. Frankenstein L, Nelles M, Slavutsky M, Schellberg D, Doesch A, Katus H et al (2007) Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents. J Heart Lung Transplant 26:1033-1039. doi:10.1007/s00392-011-0340-1 (Pubitemid 47500149)
83. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W et al (2007) Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50:1054-1060. doi:10.1016/j.jacc.2007. 04.091 (Pubitemid 47348231)
84. Michowitz Y, Goldstein E, Wexler D, Sheps D, Keren G, George J (2007) Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure. Heart 93:1046-1050. doi:10.1136/hrt.2006.102657 (Pubitemid 47310980)
85. Bayes-Genis A, Vazquez R, Puig T, Fernandez-Palomeque C, Fabregat J, Bardaji A et al (2007) Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. Eur J Heart Fail 9:802-807. doi:10.1016/j.ejheart.2007.05.001 (Pubitemid 47212830)
86. Yin WH, Chen JW, Feng AN, Lin SJ, Young S (2007) Multimarker approach to risk stratification among patients with advanced chronic heart failure. Clin Cardiol 30:397-402. doi:10.1002/clc.20171
87. Petretta M, Colao A, Sardu C, Scopacasa F, Marzullo P, Pivonello R et al (2007) NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res 17:288-296. doi:10.1016/j.ghir.2007.01.020 (Pubitemid 47109211)
88. Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T et al (2007) Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 28:1723-1730. doi:10.1093/eurheartj/ehm154 (Pubitemid 47227093)
89. MacGowan GA, Neely D, Peaston R, Wrightson N, Parry G (2010) Evaluation of NT-proBNP to predict outcomes in advanced heart failure. Int J Clin Prac 64:892-899. doi:10.1111/j.1742-1241.2010.02388.x
90. Song EK, Moser DK, Frazier SK, Heo S, Chung ML, Lennie TA (2010) Depressive symptoms affect the relationship of N-terminal pro B-type natriuretic peptide to cardiac event-free survival in patients with heart failure. J Card Fail 16:572-578. doi:10.1016/j.cardfail.2010.01.006
91. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B et al (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31:1872-1880. doi:10.1093/eurheartj/ehq158
92. Jankowska EA, Filippatos GS, von Haehling S, Papassotiriou J, Morgenthaler NG, Cicoira M et al (2011) Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. PLoS One 6:e14506. doi:10.1371/journal.pone.0014506
93. Tang WH, Shrestha K, Troughton RW, Borowski AG, Klein AL (2011) Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure. Congest Heart Fail 17:105-109. doi:10.1111/j.1751-7133.2011.00221.x
94. Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L (2011) Parathyroid hormone and vitamin D-Markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail 13:626-632. doi:10.1093/eurjhf/ hfr016
95. Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, Moure-González M, Seoane-Blanco A, Varela-Román A et al (2011) Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score. Am J Cardiol 107:938-944. doi:10.1016/j.amjcard.2010.11.011
96. von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W et al (2010) Mid-regional proadrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 12:484-491. doi:10.1093/eurjhf/hfq031
97. Van Den Broek KC, deFilippi CR, Christenson RH, Seliger SL, Gottdiener JS, Kop WJ (2011) Predictive value of depressive symptoms and B-type natriuretic peptide for new-onset heart failure and mortality. Am J Cardiol 107:723-729. doi:10.1016/j.amjcard.2010.10.055
98. Kawahara C, Tsutamoto T, Sakai H, Nishlyama K, Yamaji M, Fujii M et al (2011) Prognostic value of serial measurements of highly sensitive cardiac troponin i in stable outpatients with nonischemic chronic heart failure. Am Heart J 162:639-645. doi:10.1016/j.ahj.2011.07.007
99. Pfister R, Müller-Ehmsen J, Hagemeister J, Hellmich M, Erdmann E, Schneider CA (2011) NT-pro-BNP predicts worsening renal function in patients with chronic systolic heart failure. Intern Med J 41:467-472. doi:10.1111/j.1445-5994.2010.02203.x
100. Frankenstein L, Goode K, Ingle L, Remppis A, Schellberg D, Nelles M et al (2011) Derivation and validation of a simple clinical risk-model in heart failure based on 6 minute walk test performance and NT-proBNP status - do we need specificity for sex and beta-blockers? Int J Cardiol 147:74-78. doi:10.1016/j.ijcard.2009.08.005
101. Bajraktari G, Dini FL, Fontanive P, Elezi S, Berisha V, Napoli AM et al (2011) Independent and incremental prognostic value of Doppler-derived left ventricular total isovolumic time in patients with systolic heart failure. Int J Cardiol 148:271-275. doi:10.1016/j.ijcard.2009.09.567
102. Carlsen CM, Bay M, Kirk V, Gøtze JP, Køber L, Nielsen OW (2012) Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. Eur J Heart Fail 14:240-247. doi:10.1093/eurjhf/hfs003
103. Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P et al (2012) Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail 14:268-277. doi:10.1093/eurjhf/hfs006
104. Tziakas DN, Chalikias GK, Stakos D, Chatzikyriakou SV, Papazoglou D, Mitrousi K et al (2012) Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. Eur J Prev Cardiol 19:62-71. doi:10.1097/HJR.0b013e32833ace76
105. Bayes-Genis A, de Antonio M, Galán A, Sanz H, Urrutia A, Cabanes R et al (2012) Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 14:32-38. doi:10.1093/eurjhf/hfr156
106. Franke J, Frankenstein L, Schellberg D, Bajrovic A, Wolter JS, Ehlermann P et al (2011) Is there an additional benefit of serial NT-proBNP measurements in patients with stable chronic heart failure receiving individually optimized therapy? Clin Res Cardiol 100:1059-1067. doi:10.1007/s00392-011-0340-1
107. Jungbauer CG, Riedlinger J, Buchner S, Birner C, Resch M, Lubnow M et al (2011) High-sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N-terminal pro-b-type natriuretic peptide. Clin Chem Lab Med 49:1899-1906. doi:10.1515/CCLM.2011.251
108. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H et al (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4:569-577. doi:10.1161/CIRCHEARTFAILURE.111. 962654
109. de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A (2012) Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am Heart J 163:821-828. doi:10.1016/j.ahj.2012.03.004
110. Balling L, Kistorp C, Schou M, Egstrup M, Gustafsson I, Goetze JP et al
111. Al-Najjar Y, Witte KK, Clark AL (2012) Chronotropic incompetence and survival in chronic heart failure. Int J Cardiol 157:48-52. doi:10.1016/j. ijcard.2010.11.018
112. Christensen HM, Frystyk J, Faber J, Schou M, Flyvbjerg A, Hildebrandt P et al (2012) a-Defensins and outcome in patients with chronic heart failure. Eur J Heart Fail 14:387-394. doi:10.1093/eurjhf/hfs021
113. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC et al (2004) Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43:1590-1595. doi:10.1016/j.jacc.2003.10.066 (Pubitemid 38561338)